Anna Laemmerer

Mrs. Anna Laemmerer

Medical University of Vienna, Department of Pediatrics and Adolescent Medicine
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
SKSebastian Kallus
Sebastian Kallus
BEBernhard Englinger
Bernhard Englinger
JSJulia Senkiv
Julia Senkiv
ALAnna Laemmerer
Anna Laemmerer
PHPetra Heffeter
Petra Heffeter
BKBernhard K. Keppler
Bernhard K. Keppler

18 December 2020 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
LMLisa Mayr
Lisa Mayr
AGArmin Guntner
Armin Guntner
SMSibylle Madlener
Sibylle Madlener
MSMaria T. Schmook
Maria T. Schmook
APAndreas Peyrl
Andreas Peyrl
JGJohannes Gojo
Johannes Gojo
Targeting oncogenic fusion-genes in pediatric high-grade gliomas (pHGG) with entrectinib has emerged as a highly promising therapeutic approach. Despite ongoing clinical studies, to date, no reports on the treatment of cerebrospinal fluid (CSF) disseminated fusion-positive pHGG exist. Moreover, clinically important information of combination with other treatment modalities such as intrathecal therapy, radiotherapy and other targeted agents is missing. We report on our clinical experience of entrectinib therapy in two CSF disseminated ROS1/NTRK-fusion-positive pHGG cases. Combination of entrectinib with radiotherapy or intrathecal chemotherapy appears to be safe and has the potential to act synergistically with entrectinib treatment. In addition, we demonstrate CSF penetrance of entrectinib for the first time in patient samples suggesting target engagement even upon CSF dissemination. Moreover, in vitro analyses of two novel cell models derived from one case with NTRK-fusion revealed that combination therapy with either a MEK (trametinib) or a CDK4/6 (abemaciclib) inhibitor synergistically enhances entrectinib anticancer effects. In summary, our comprehensive study, including clinical experience, CSF penetrance and in vitro data on entrectinib therapy of NTRK/ROS1-fusion-positive pHGG, provides essential clinical and preclinical insights into the multimodal treatment of these highly aggressive tumors. Our data suggest that combined inhibition of NTRK/ROS1 and other therapeutic vulnerabilities enhances the antitumor effect, which should be followed-up in further preclinical and clinical studies.

30 March 2021 in Inorganic Chemistry Frontiers
Verified
Journal Article
Open access
PDF file
MMMarlene Mathuber
Marlene Mathuber
MGMichael Gutmann
Michael Gutmann
MFMery La Franca
Mery La Franca
PVPetra Vician
Petra Vician
ALAnna Laemmerer
Anna Laemmerer
CKChristian Kowol
Christian Kowol
Receptor tyrosine kinase inhibitors have become a central part of modern targeted cancer therapy. However, their curative potential is distinctly limited by both rapid resistance development and severe adverse effects. Consequently, tumor-specific drug activation based on prodrug designs, exploiting tumor-specific properties such as hypoxic oxygen conditions, is a feasible strategy to widen the therapeutic window. After proof-of-principal molecular docking studies, we have synthesized two cobalt(III) complexes using a derivative of the clinically approved Abelson (ABL) kinase and fibroblast growth factor receptor (FGFR) inhibitor ponatinib. Acetylacetone (acac) or methylacetylacetone (Meacac) have been used as ancillary ligands to modulate the reduction potential. The ponatinib derivative, characterized by an ethylenediamine moiety instead of the piperazine ring, exhibited comparable cell-free target kinase inhibition potency. Hypoxia-dependent release of the ligand from the cobalt(III) complexes was proven by changed fluorescence properties, enhanced downstream signaling inhibition and increased in vitro anticancer activity in BCR-ABL- and FGFR-driven cancer models. Respective tumor-inhibiting in vivo effects in the BCR-ABL-driven K-562 leukemia model were restricted to the cobalt(III) complex with the higher reduction potential and confirmed in a FGFR-driven urothelial carcinoma xenograft model. Summarizing, we here present for the first time hypoxia-activatable prodrugs of the clinically approved tyrosine kinase inhibitor ponatinib and a correlation of the in vivo activity with their reduction potential.